Sanofi completes closing of collaborative agreement with Janssen to develop & commercialize vaccine candidate for extraintestinal pathogenic?E.?coli

Sanofi announces completion of closing for its collaborative agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company to develop and commercialize the vaccine candidate for extraintestinal pathogenic?E.?coli?(9-valent) (ExPEC9V). 

Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis, causing approximately 10 million cases of invasive ExPEC disease annually, worldwide. It is associated with increased hospitalizations, mortality and antimicrobial resistance resulting in significant healthcare and societal costs.

Thomas Triomphe, executive vice president, vaccines, Sanofi, said: “At Sanofi, we believe in the power of partnership to deliver true innovation. In this case, we’re bringing together Janssen’s robust science and Sanofi’s worldwide manufacturing footprint and expertise in launching innovative vaccines. We look forward to delivering this potential first-in-class vaccine designed to help older adults around the world live longer, healthier lives.”

ExPEC9V is currently being assessed via the phase 3 E.mbrace?trial?which continues to enroll patients.

Sanofi is an innovative global healthcare company, driven by one purpose: the company chase the miracles of science to improve people’s lives. Its team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!